IR@tangotx.com Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. For more information, please visit www.tangotx.com. Investors and Media: Elizabeth Hickin BOSTON, May 27, 2025 ( ...

Core Viewpoint - Tango Therapeutics, Inc. is set to report its first quarter 2025 financial results on May 12, 2025, before the U.S. financial markets open, and will not hold a conference call following the announcement [1]. Company Overview - Tango Therapeutics is a clinical-stage biotechnology company focused on discovering novel drug targets and advancing precision medicine for cancer treatment [2]. - The company employs the genetic principle of synthetic lethality to identify and develop therapies targeting critical cancer-related objectives [2].